The remarkable clinical efficacy observed with inhibitors of immune checkpoints such as programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) [3–5] has become increasingly important in studying the role of the immune cell system in controlling tumor growth in various types of cancer. Here, PDCD1 is linked to neoplasm.